Search results
Showing 271 to 285 of 309 results for breast cancer
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
In development Reference number: GID-TA11771 Expected publication date: TBC
Discontinued Reference number: GID-TA11339
Biographies and registered interests for members of the Technology Appraisal Committee A
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
We regularly review our diagnostics guidance. If there is no new research or evidence available that would have a material effect on the guidance, it gets moved to the static list.
Early Cancer Diagnosis: 75% of cases diagnosed at stage 1 or 2 by 2028.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
We have also recommended osimertinib for routine use on the NHS today.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.